Alzamend Neuro, INC. (ALZN) — 8-K Filings

All 8-K filings from Alzamend Neuro, INC.. Browse 29 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (29)

Alzamend Neuro Files 8-K — Nov 18, 2025 Risk: low
Alzamend Neuro, Inc. filed an 8-K on November 18, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is in the pharma
Alzamend Neuro Files 8-K with Corporate Updates — Oct 14, 2025 Risk: low
Alzamend Neuro, Inc. filed an 8-K on October 14, 2025, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements and exhib
Alzamend Neuro Files 8-K on Equity Sales — Oct 9, 2025 Risk: medium
Alzamend Neuro, Inc. filed an 8-K on October 9, 2025, reporting unregistered sales of equity securities. The filing also includes financial statements and exhib
Alzamend Neuro Files 8-K on Equity Sales — Sep 25, 2025 Risk: medium
Alzamend Neuro, Inc. filed an 8-K on September 25, 2025, reporting unregistered sales of equity securities and financial statements. The company, incorporated i
Alzamend Neuro Files 8-K on Equity Sales — Aug 1, 2025 Risk: medium
Alzamend Neuro, Inc. filed an 8-K on August 1, 2025, reporting unregistered sales of equity securities. The filing also includes financial statements and exhibi
Alzamend Neuro Files 8-K on Operations — Jul 23, 2025 Risk: low
Alzamend Neuro, Inc. filed an 8-K on July 23, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and
Alzamend Neuro Files 8-K with Corporate Updates — Jul 9, 2025 Risk: low
Alzamend Neuro, Inc. filed an 8-K on July 9, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company, incorp
Alzamend Neuro Files 8-K with Corporate Updates — May 8, 2025 Risk: low
Alzamend Neuro, Inc. filed an 8-K on May 8, 2025, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial sta
Alzamend Neuro Files 8-K on Shareholder Votes and Financials — Apr 25, 2025 Risk: low
Alzamend Neuro, Inc. filed an 8-K on April 25, 2025, reporting on matters submitted to a vote of security holders and financial statements. The company, incorpo
Alzamend Neuro Files 8-K for Bylaws, Exhibits — Mar 3, 2025 Risk: low
Alzamend Neuro, Inc. filed an 8-K on March 3, 2025, reporting amendments to its Articles of Incorporation or Bylaws and submitting financial statements and exhi
Alzamend Neuro Files 8-K on Agreements and Equity Sales — Feb 28, 2025 Risk: medium
Alzamend Neuro, Inc. filed an 8-K on February 28, 2025, reporting on the entry into a material definitive agreement, unregistered sales of equity securities, an
Alzamend Neuro Files 8-K on Financials — Dec 12, 2024 Risk: medium
Alzamend Neuro, Inc. filed an 8-K on December 12, 2024, reporting on its results of operations and financial condition. The filing details financial statements
Alzamend Neuro Files 8-K with Financial Updates — Oct 15, 2024 Risk: low
Alzamend Neuro, Inc. filed an 8-K on October 15, 2024, reporting on financial statements and exhibits. The company, incorporated in Delaware, is involved in pha
Alzamend Neuro Enters Material Definitive Agreement — Oct 3, 2024 Risk: medium
Alzamend Neuro, Inc. announced on October 3, 2024, that it has entered into a Material Definitive Agreement. The company also filed financial statements and exh
Alzamend Neuro Files 8-K — Jul 31, 2024 Risk: low
Alzamend Neuro, Inc. filed an 8-K on July 31, 2024, reporting on financial statements and exhibits, and a Regulation FD Disclosure. The company, incorporated in
Alzamend Neuro Files 8-K with Corporate Updates — Jul 12, 2024 Risk: low
Alzamend Neuro, Inc. filed an 8-K on July 12, 2024, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial s
Alzamend Neuro Files 8-K on Shareholder Votes and Financials — Jul 8, 2024 Risk: low
Alzamend Neuro, Inc. filed an 8-K on July 8, 2024, reporting on matters submitted to a vote of security holders and including financial statements and exhibits.
Alzamend Neuro Files 8-K — May 22, 2024 Risk: low
Alzamend Neuro, Inc. filed an 8-K on May 22, 2024, reporting on Regulation FD disclosures and financial statements. The company, incorporated in Delaware, has i
Alzamend Neuro Files 8-K — May 15, 2024 Risk: low
Alzamend Neuro, Inc. filed an 8-K on May 15, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain sp
Alzamend Neuro Files 8-K for Financial Statements — May 13, 2024 Risk: low
Alzamend Neuro, Inc. filed an 8-K on May 13, 2024, to report financial statements and exhibits. The filing does not contain specific financial figures or detail
Alzamend Neuro Changes Independent Accountants — May 9, 2024 Risk: medium
Alzamend Neuro, Inc. filed an 8-K on May 9, 2024, to report a change in its certifying accountant. The company has dismissed its previous independent registered
Alzamend Neuro Terminates Material Agreement — May 7, 2024 Risk: medium
Alzamend Neuro, Inc. announced on May 7, 2024, the termination of a material definitive agreement. The company also disclosed information related to Regulation
Alzamend Neuro Files 8-K on Voting Matters and Financials — May 1, 2024 Risk: low
Alzamend Neuro, Inc. filed an 8-K on May 1, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing details the
Alzamend Neuro Files 8-K: Material Agreement & Equity Sales — Apr 30, 2024 Risk: medium
Alzamend Neuro, Inc. announced on April 30, 2024, that it entered into a material definitive agreement. The company also reported the creation of a direct finan
Alzamend Neuro Faces Delisting, Reports Equity Sales — Mar 29, 2024 Risk: high
Alzamend Neuro, Inc. filed an 8-K on March 29, 2024, reporting an entry into a material definitive agreement and a notice of delisting or failure to satisfy con
Alzamend Neuro Files 8-K for Material Agreements — Mar 22, 2024 Risk: medium
Alzamend Neuro, Inc. announced on March 22, 2024, that it entered into a Material Definitive Agreement. The company also made material modifications to the righ
Alzamend Neuro Files 8-K with Bylaw Amendments — Mar 7, 2024 Risk: low
Alzamend Neuro, Inc. filed an 8-K on March 7, 2024, reporting amendments to its Articles of Incorporation or Bylaws and including financial statements and exhib
Alzamend Neuro Faces Delisting, Sells Unregistered Equity — Feb 2, 2024
Alzamend Neuro, Inc. filed an 8-K on February 2, 2024, reporting a material definitive agreement, unregistered sales of equity securities, and amendments to its
Alzamend Neuro 8-K: Executive Compensation Arrangements Updated — Jan 5, 2024
Alzamend Neuro, Inc. filed an 8-K on January 5, 2024, reporting changes in its executive compensation arrangements. This filing indicates potential adjustments

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX